Get the Stockscreener App
91.52
1.00%
0.91
Pre-market:
91.52
Illumina Inc stock is traded at $91.52, with a volume of 2.30M.
It is up +1.00% in the last 24 hours and up +13.87% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$90.61
Open:
$91.54
24h Volume:
2.30M
Relative Volume:
1.06
Market Cap:
$13.93B
Revenue:
$4.34B
Net Income/Loss:
$-965.00M
P/E Ratio:
-15.08
EPS:
-6.07
Net Cash Flow:
$869.00M
1W Performance:
+2.29%
1M Performance:
+13.87%
6M Performance:
-32.31%
1Y Performance:
-16.98%
1-Day Range:
$89.39
$91.66
1-Week Range:
$88.65
$91.66
52-Week Range:
$68.70
$156.66
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
91.52 | 13.93B | 4.34B | -965.00M | 869.00M | -6.07 |
|
TMO
Thermo Fisher Scientific Inc
|
404.37 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.47 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
530.50 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
117.64 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
158.58 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Infinity Bio Secures $8M Series A and Acquires Serimmune to Dominate Antibody Reactome Market - Stock Titan
DNA/Gene Microarray Market Future Trends and Scope Analysis - openPR.com
How the DNA Data Storage Market Will Evolve by 2032Growth, - openPR.com
Saudia Arabia Introduces Strategic Healthcare Vision and Global Partnerships at BIO 2025 - GlobeNewswire Inc.
Next-Gen Diagnostics Drive Biochips Market Growth: Thermo Fisher, Illumina, and PerkinElmer at the Forefront - openPR.com
Illumina and Science Centre Singapore partner for Brain Fest 2025 - Illumina
Video: Inspiring the next generation of scientists in Singapore - Illumina
Clinical Oncology Next Generation Sequencing Market Detailed - openPR.com
Illumina (ILMN) Price Target Boosted by Canaccord Analyst | ILMN Stock News - GuruFocus
Video: Two Illumina scientists share their “why” - Illumina
Breaking Down Illumina: 11 Analysts Share Their Views - Benzinga
lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics - Illumina
Lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics - marketscreener.com
Piper Sandler maintains Illumina stock Overweight, $185 target By Investing.com - Investing.com UK
Long Read Sequencing Market Top Key Players Analysis - openPR.com
Gemeinsam Genomik neu denken - Illumina
Microarray Biochips Market is Booming Worldwide |Illumina,Qiagen,Eppendorf - openPR.com
Single-cell Omics Market Projected to Witness Growth with - openPR.com
Tumor-Derived Exosomes Market Set to Witness Significant - openPR.com
Hereditary Testing Market Future Business Opportunities - openPR.com
Next Generation Sequencing Market to Witness Upsurge in Growth - openPR.com
Does Illumina (ILMN) Have Good Long-Term Growth Prospects? - Insider Monkey
Nucleic Acid Isolation and Purification Market Size, Trends & - openPR.com
Illumina’s DNA Test Tech Infringes Hospital Patent, Suit Claims - Bloomberg Law News
Microbiome Sequencing Market Outlook 2025-2029 | Affordable Sequencing Instruments Expand Market Access for Smaller Labs - Yahoo
Digital Genome Market Deep Research Report on AI-Driven DNA Analysis Trends | Illumina, Thermo Fisher Scientific - openPR.com
Forensic Genomics Market Research 2025Global Trends, Opportunity, and Forecasts 2020-2030 - GlobeNewswire Inc.
Cancer Profiling Market Is Booming So Rapidly 2025-2032 - openPR.com
Hereditary Testing MarketGlobal Industry Trends, Opportunity, and Forecast, 2020-2030: Key Players Like Illumina and Myriad Genetics Leading the Charge - Yahoo Finance
Next-Gen RNA Sequencing Market | Personalized Medicine & Future - openPR.com
Gene Panel Market Projected to Witness Massive GrowthIllumina, Inc., Thermo Fisher Scientific - openPR.com
Illumina Connected Insights - Technology Networks
Illumina Inc (ILMN) Stock Price Down 3.31% on May 30 - GuruFocus
Genotyping Assay Market Deep Research Report Highlights Key AdvancementsIllumina, Thermo Fisher Scientific - openPR.com
Illumina’s PromoterAI unlocks rare disease clues in noncoding genome - statnews.com
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain? - Nasdaq
Epigenetics Market Analysis 2025-2033: Advances in DNA - openPR.com
Illumina introduces PromoterAI for rare disease diagnosis By Investing.com - Investing.com South Africa
Illumina Inc.: Tackling Global Headwinds With Strategic Market Diversification! - Smartkarma
Illumina, Inc. (ILMN) Unveils AI Breakthrough for Rare Disease Diagnosis - Insider Monkey
Illumina introduces PromoterAI for rare disease diagnosis - Investing.com Australia
Operating a speedy, high-tech NGS lab in remote Australia - Illumina
Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis - Nasdaq
Bioinformatics Market Detailed in New Research ReportThermo Fisher Scientific, Illumina - openPR.com
DNA giant Illumina spawned an ecosystem of competitors and customers - Endpoints News
Illumina widens access to cancer tests with Medicare and new CDx - Yahoo Finance
Patent Fight Breaks Out over Genetic Sequencing - Orthopedics This Week
Illumina at Bernstein Conference: Strategic Insights and Challenges - Investing.com
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Illumina Inc Stock (ILMN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thaysen Jacob | Chief Executive Officer |
May 12 '25 |
Buy |
80.88 |
6,500 |
525,732 |
77,540 |
| Thaysen Jacob | Chief Executive Officer |
May 13 '25 |
Buy |
80.84 |
5,850 |
472,942 |
83,390 |
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):